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Background: The progression of Alzheimer’s disease (AD) is associated with an increase of phosphorylated tau in
the brain. One of the earliest phosphorylated sites on tau is Ser262 that is preferentially phosphorylated by
microtubule affinity regulating kinase (MARK), of which four isoforms exist. Herein we investigated the expression of
MARK1-4 in the hippocampus of non-demented elderly (NDE) and AD cases.
Results: In situ hybridization revealed a uniform, neuronal distribution of all four isoform mRNAs in NDE and AD.
Immunohistochemical analyses using isoform-selective antibodies demonstrated that MARK4 in a phosphorylated
form colocalizes with p-tau Ser262 in granulovacuolar degeneration bodies (GVDs) that progressively accumulate in AD.
In contrast MARK4 is largely absent in the neuronal cytoplasm. MARK3 was localized to a subset of the GVD-containing
neurons and also had a weak general cytoplasmic neuronal staining in both NDE and AD. These results suggest that in
AD, phosphorylated MARK3 and MARK4 are sequestered and proteolysed in GVDs. MARK1 and MARK2 were absent in
GVDs and exhibited relatively uniform neuronal expressions with no apparent differences between NDE and AD.
Conclusion: We found that the phosphorylated and fragmented forms of MARK4 and to some extent MARK3 are
present in GVDs in AD, and that this expression is highly correlated with phosphorylation of tau at Ser262. This may
represent a cellular defense mechanism to remove activated MARK and p-tau Ser262 from the cytosol, thereby reducing
the phosphorylating effect on tau Ser262 that appears to be a critical step for subsequent neurodegeneration.
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Tau protein was identified as the principal component of
Alzheimer’s disease (AD) neurofibrillary tangles (NFTs)
in the 1980s [1-3]. This finding led to the identification
of many kinases that have the ability to phosphorylate
tau and the description of more than 45 phosphorylation
sites present on paired helical filament (PHF) tau [4-6].
Indeed, phosphorylation at specific tau epitopes is crit-
ical for neurofibrillary tangle formation and subsequent
neurodegeneration [7,8]. One of the earliest sites on tau
to become phosphorylated in the AD brain is Ser262 [9],
which is located in the KXGS motif in one of the* Correspondence: gabriel.von.euler@ki.se
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unless otherwise stated.microtubule repeat domains, and that can be phosphory-
lated by MARK1-4 [10-13], a family of four highly con-
served kinases [10,12,14].
It is known from in vitro studies that MARK phosphor-
ylation of tau at the Ser262 site causes detachment of tau
from microtubules and their subsequent destabilization
makes tau available for further phosphorylation by other
kinases [10,15], and MARK phosphorylation can induce
mis-sorting of phosphorylated tau [16]. Tau Ser262 phos-
phorylation and mislocalization are early events in a
mouse model of tau pathology [17], and studies in Dros-
ophila have demonstrated a crucial role of the MARK
phosphorylation site on tau for neurodegeneration [18,19].
A previous study that examined MARK expression in
the human brain reported increased MARK1 expression
in AD, but lacked a robust confirmation of the isoform-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ceeded in developing and identifying specific antibodies
towards each of the four MARK isoforms. Using these
specific antibodies and a monoclonal antibody towards
unphosphorylated tau we were able to demonstrate an
increased interaction of MARK2 and MARK4 in AD
hippocampal tissue compared to controls using the in
situ proximity ligation assay [13,21].
Granulovacuolar degeneration bodies (GVDs) are
double membrane vacuoles present in neurons, having
an immunohistochemical signature that suggests that
they derive from the autophagic system [22]. GVDs also
stain for cytoskeletal proteins such as neurofilament,
tubulin tau and tau kinases [1,23-28]. GVDs have been
shown to be more frequent in AD brains compared to in
age-matched controls [29], and a recent study suggests
that GVD accumulation is specific to AD, since GVD
frequency correlated with every measure of AD severity
but was not different in any other non-AD tauopathies
compared to control brains [30].
In the present study we characterized the intracellular
localization of the four MARK isoforms and investigated
whether their expression levels were elevated in the
hippocampus in AD. We observed abundant neuronal
mRNA expression of all MARK isoforms in both AD
and NDE cases. At the protein level we determined that
MARK1 and MARK2 were abundantly expressed in
neuronal cytoplasm, but that expression levels did not
increase in AD. In addition to a general cytoplasmic ex-
pression that did not change in AD, MARK3 was de-
tected in a minor fraction of GVDs that are evident in
neurons in AD. The expression of MARK4 was below
the detection level in normal brain tissue, but was highly
present in a phosphorylated form in GVDs in AD, where
it colocalized with tau Ser262 phosphorylation.
Methods
Human brain tissues
All studies of human tissue have been reviewed and ap-
proved by the ethical review board in Stockholm,
Sweden. All human brain tissues included in this study
were acquired from the Netherlands Brain Bank where
informed consent for donated tissue had been given by
all patients or their next of kin. Neuropathological diag-
nosis was based on NIA-Reagen criteria with both
CERAD and Braak staging. Case and tissue details are
summarized in Table 1. Both paraffin embedded (4 μm
sections) and fresh frozen tissue (8–10 μm sections)
were used.
In situ hybridization
In situ hybridization was performed on 2 NDE and
4 AD cases. 35S-UTP labeled cRNA probes were synthe-
sized by in vitro transcription with the MAXIscript Kit(Ambion) from a synthetic DNA fragment corresponding
to part of the coding sequence of human MARK1 (nucleo-
tides 1537–2116 of accession no NM_018650), human
MARK2 (1629–2228 of NM_001039469), human MARK3
(1823–2412 of NM_001128918) or human MARK4 (1181–
1781 of NM_031417) cloned into a pGEM-5Z (+) vector
(GeneART). Probes were designed to minimize cross-
reactivity towards the other isoforms as summarized in
Table 2. Probes were synthesized in both antisense and
sense directions and hybridized to adjacent sections to con-
trol for labeling specificity. The rest of the protocol was
conducted as previously described [31]. Briefly, sections
were fixed with 4% paraformaldehyde (PFA), rinsed 3 times
in 2× standard sodium citrate buffer (2× SSC), equilibrated
in 0.1 M triethanolamine, and treated with 0.25% acetic an-
hydride in 0.1 M triethanolamine. Sections were equili-
brated in chloroform and dehydrated through an ethanol
series. Hybridization with [35S]-labeled cRNA probes was
performed at 59°C overnight under a coverslip. Following
hybridization sections were treated with 20 μg/ml
RNase A for 45 minutes at 37°C, washed in a series of
decreasing SSC-containing solutions with a final high
stringency wash of 0.1× SSC and 1 mM DTT at 69°C.
Sections were then dehydrated and exposed to Kodak
Biomax MR-2 film, dipped in NTB2 emulsion (Kodak)
and exposed at 4°C prior to development and counter-
staining with hematoxylin.Primary antibodies
The following rabbit antibodies were used: human
MARK1 (AGG6175; AstraZeneca), raised against the
peptide DGSEAYRPGT; human MARK2 (AGG6218;
AstraZeneca), raised against SVLSTSTNRSRNS; human
MARK3 (#9311; Cell Signaling); human MARK4 (#4834;
Cell Signaling); phospho-MARK family (PA5-17495;
Pierce); p-tau Ser262 (AGG5759; AstraZeneca), raised
against KSKIGS*TENLKHQPGGC (*phosphorylated)
and affinity-purified first against the phosphorylated
peptide and then against corresponding non-phosp-
horylated peptide; p-tau Ser422 (EPR2866; Epitomics);
CK1δ (ab37971; AbCam). In addition we used the fol-
lowing mouse monoclonal antibodies: p-tau Ser202/
Thr205 (AT8; Innogenetics), p-tau Ser212/Thr214 (AT100,
Innogenetics), total-tau (tau-13; SantaCruz) and β-actin
(AC-15; Sigma).Immunohistochemistry
Immunohistochemistry was conducted as previously de-
scribed [31]. Briefly, stainings were performed using an
Ventana Discovery XT automated staining module using
the OmniMap DAB kit (Ventana Medical Systems)
according to the manufacturer’s instructions. Sections
were scanned with a NanoZoomer 2.0-HT slide scanner
Table 1 Case characteristics
Case # Brain region Format Gender Age Diagnosis Braak stage PMI (h:m) pH CSF Brain weight (g) ApoE genotype
In situ hybridization
6 HC FF M 85 NDE I 4:15 6.68 1181 4:4
7 HC FF F 91 NDE I 7:45 6.90 1074 3:3
27 HC FF F 84 AD V 5:55 6.42 1217 3:3
29 HC FF F 89 AD V 4:40 6.28 1022 4:3
19 HC FF F 82 AD VI 4:00 6.66 1110 4:4
21 HC FF F 89 AD VI 4:30 6.35 1185 4:3
Immunohistochemistry/Immunofluorescence
1 HC FF M 74 NDE 0 8:00 6.75 1317 3:2
22 HC FF F 77 NDE I 5:30 6.74 1343 4:3
4 HC FF M 78 NDE I 6:55 6.42 1332 3:3
30 HC FFPE F 83 NDE I 5:30 6.48 1294 3:2
6 HC FFPE M 85 NDE I 4:15 6.68 1181 4:4
7 HC FFPE, FF F 91 NDE I 7:45 6.90 1074 3:3
9 HC FFPE M 81 NDE II 5:30 6.46 1348 3:3
25 HC FFPE, FF M 87 NDE II 4:55 6.31 1052 3:3
10 HC FFPE M 82 NDE IV 10:00 6.53 1528 4:3
38 HC FF F 95 AD/LBV IV 5:25 6.10 1091 3:3
13 HC FFPE, FF M 64 AD IV 6:00 6.62 1128 3:3
26 HC FF F 86 AD IV 5:05 6.62 998 4:3
31 HC FFPE F 94 AD IV 5:05 6.52 1170 4:3
11 HC FF F 71 AD V 5:30 6.36 1125 4:3
24 HC FF M 75 AD V 5:15 6.39 1178 4:3
32 HC FF F 78 AD V 4:50 6.22 1105 4:4
33 HC FFPE F 82 AD V 4:35 6.49 1104 4:3
14 HC FFPE F 84 AD V 7:15 6.58 1129 4:3
12 HC FF F 84 AD V 4:50 6.67 1092 4:4
28 HC FFPE M 87 AD V 6:10 6.14 1088 3:3
16 HC FF F 88 AD V 5:10 6.62 1075 4:3
29 HC FFPE F 89 AD V 4:40 6.28 1022 4:3
34 HC FFPE F 67 AD VI 5:50 6.75 945 3:3
18 HC FFPE, FF F 68 AD VI 3:50 6.50 1095 3:2
35 HC FFPE F 69 AD VI 4:45 6.33 862 3:3
37 HC FF F 87 AD VI 4:00 6.80 1048 4:3
21 HC FF F 89 AD VI 4:30 6.35 1185 4:3
Western blot
1 HC FF M 74 NDE 0 8:00 6.75 1317 3:2
4 HC FF M 78 NDE I 6:55 6.42 1332 3:3
6 HC FF M 85 NDE I 4:15 6.68 1181 4:4
7 HC FF F 91 NDE I 7:45 6.90 1074 3:3
27 HC FF F 84 AD V 5:55 6.42 1217 3:3
29 HC FF F 89 AD V 4:40 6.28 1022 4:3
19 HC FF F 82 AD VI 4:00 6.66 1110 4:4
AD = Alzheimer’s disease; FF = fresh frozen; FFPE = formalin-fixed paraffin embedded; HC = hippocampus; LBV = Lewy body variant; NDE = non-demented elderly;
PMI = post mortem interval; CSF = cerebrospinal fluid.
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Table 2 Cross-reactivity of probes used for in situ
hybridization
MARK1 MARK2 MARK3 MARK4
Length 580 bp 600 bp 590 bp 601 bp
MARK1 100% 38.7% 55.6% 50.4%
MARK2 51.9% 100% 36.1% 52.6%
MARK3 55.9% 39.3% 100% 52.2%
MARK4 48.1% 42.3% 46.6% 100%
Percentages are overall sequence identity of probes toward each MARK
family isoform.
Figure 1 Characterization of MARK 1–4 mRNA expression by in situ h
individual isoform of MARK in fresh-frozen sections of hippocampus from t
AD cases (C, #27 and D, #29), revealing expression and strong overlap of al
fields. The CA2 field is denoted with red arrowheads in the MARK2 panel. S
negative control, with a representative picture presented in the inset. (E) P
hematoxylin from the case in A, from the area indicated by the box in A. S
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sections using NDP.view software.
Immunofluorescence
Multi-label immunofluorescent staining with two or
three rabbit antibodies was carried out using the tyra-
mide signal amplification (TSA) kit (PerkinElmer) ac-
cording to the manufacturers’ instructions. This allows
for a very extensive dilution of the primary antibody,
reducing cross-reactivity of the second secondary anti-
body to the first primary antibody to a minimum.
Double-labeling was carried out with one TSA-reaction
followed by normal immunofluorescent staining. Triple-
labeling entailed two TSA-reactions followed by normalybridization in the hippocampus. In situ hybridization towards each
wo representative NDE cases (A, #6 and B, #7) and two representative
l four isoforms in the dentate gyrus (black arrow head) and all CA
ections hybridized with sense-transcribed probes were used as
hotomicrograph of emulsion-dipped sections counterstained with
cale bars: (A) 1 mm; (E) 100 μm.
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TSA-reactions were swine anti-rabbit- HRP (Dako). For
immunofluorescence donkey anti-rabbit conjugated to
FITC or Cy3 (Jackson ImmunoResearch) or goat anti-
rabbit Alexa Fluor 594 (Invitrogen) were used. Images
were captured using a Leica DMI6000 CS confocal
microscope connected to a Leica TCS SP5 scanner.Figure 2 Expression of MARK1-3 in hippocampal brain sections. Low
from an NDE case (#7), with antibodies towards MARK1-3. MARK1 expressio
bodies intensely labeled in this area. Less expression is detectable in the CA
in the CA layers of the hippocampus, particularly strong in CA2 and dentat
for this isoform. MARK3 expression on the cytoplasmic level is only detecta
High magnification images are included in Figure 2. Scale bar: 1 mm.Quantification of colocalization
Colocalization of MARK3 or MARK4 and GVD-marker
CK1δ was evaluated using ImageJ 1.47v software. Briefly,
Z-stack images of individual neurons were captured
using confocal microscopy (3–12 neurons/case; 4–6
cases), thresholded and converted to 8-bit images. Green
and red channel images were then superimposed onmagnification micrographs of three adjacent hippocampal sections
n is particularly strong in the CA2-layer, with apical dendrites and cell
3, CA4 and DG. MARK2 expression is more homogenously expressed
e gyrus (DG), although considerable inter-individual difference existed
ble in the CA2 layer. Inset images are boxed areas in the CA2 layer.
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Green and Red Puncta Colocalization Macro (Developed
by D. J. Shiwarski, R. K. Dagda and C.T. Chu). The num-
ber and size of single-stained and double-stained parti-
cles were then determined using the Particle Analyzer
tool in ImageJ.
Cell culture and transfections
The human embryonic kidney cell line HEK293 was pur-
chased from ATCC (CRL-1573). Cells were grown in
DMEM/F12 medium with Glutamax (Invitrogen) and
supplemented with 10% heat-inactivated fetal calf serum
(FCS, Hyclone). Cells were seeded in T225 flasks (Corn-
ing) and transfected with a total of 63 μg plasmid cDNA
(HA-tagged MARK3 or MARK4)/flask at 70% conflu-
ence. Lipofectamine LTX with PLUS reagent (Invitrogen)Figure 3 Immunohistochemical characterization of MARK1-4 protein
immunohistochemical staining from the CA2 area of representative NDE an
MARK isoform. Neurons containing granulovacuolar degeneration bodies (G
and MARK2 antibodies reveal a diffuse cytoplasmic staining but no positive
staining in GVDs as this is observed in all GVDs with the MARK4 antibody a
50 μm. (I) Quantification of the number of MARK3, MARK4 or CK1δ neuron
n = 4–5 NDE; 7–10 AD. Data depicts means ± SEM. *p < 0.05, **p < 0.01 by S
n = 1(Br0); 2-3(Br1); 1(Br2); 2(Br4); 2-5(Br5); 3(Br6).was used for transfections according to the manufac-
turer’s manual. Briefly, PLUS reagent was mixed with
plasmid DNA in cell culture medium without serum and
incubated for 5 min. Lipofectamine LTX was added
and incubated an additional hour. The complexes were
added to the cells and transfections were performed for
24 hours.Western blotting
The transfected HEK293 cells were lysed in buffer con-
taining 50 mM TrisHCl, pH 7.2, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 10 mM NaF, 1 mM Na3O4V,
and 1 complete protease inhibitor cocktail tablet (Roche)/
10 ml buffer. The cells were incubated with lysis buffer for
5 min on ice before scraping from the wells. Samples wereexpression in the hippocampus. (A-H) Photomicrographs of
d AD cases (#9, #7, #13, #18 and #34) with specific antibodies for each
VDs) are marked with arrowheads and magnified in insets. MARK1
staining in GVDs (red arrowheads). Black arrowheads indicate positive
nd in some but not all GVDs with the MARK3 antibody. Scale bar:
s with granular immunoreactivity in the CA1-CA2 area or CA3-CA4 area.
tudent’s unpaired t-test. (J) Data in (I) plotted against Braak stage.
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on ice and centrifuged at 14000 rpm at 4°C.
100–150 mg of human fresh frozen samples (sectioned
adjacently to samples used for in situ hybridization and
immunohistochemistry) were lysed on ice in ice-cold
lysis buffer containing 50 mM Tris acetate, pH 7.4,
5 mM EDTA, 5 mM EGTA and one complete protease
inhibitor cocktail tablet (Roche)/10 ml buffer and vor-
texed. Tissue extraction reagent (Invitrogen) with one
complete protease inhibitor cocktail tablet/10 ml was
added before sonicating the samples using a Sonifer cell
disrupter B15 (Branson) in 5 s intervals placing the sam-
ples on ice in between pulsing. Samples were centrifuged
at 1000 × g at 4°C for 5 min. The protein contents in su-
pernatants from cell lysates and human tissue extrac-
tions were measured using the BCA Protein Assay kit
(Pierce). 1 μg proteins from cell lysates and 18 μg pro-
teins from human tissue extractions, respectively, were
separated in NuPAGE Novex 4-12% Bis-Tris mini gels
(Invitrogen) and transferred to PVDF membranes using
the iBlot dry blotting device (Invitrogen). Membranes
were blocked in Starting Block T20 PBS Blocking Buffer
(Thermo Scientific) before being incubated overnight
with primary antibodies at 4°C in PBS containing 0.05%
Tween20 (PBS-T). Membranes were washed with PBS-T
and incubated with horseradish-peroxidase (HRP)-con-
jugated secondary antibodies (Amersham Biosciences).
After washing, the membranes were developed using the
Amersham enhanced chemiluminescence (ECL) western
blotting detection system (GE Healthcare). Average den-Figure 4 Colocalization analysis of MARK3 and MARK4 with GVD-mar
(B) MARK4 (FITC) and GVD-marker CK1δ (Alexa Fluor 594, red) in GVD-cont
Z-stack (first three images) and a 3D-reconstruction of a Z-stack imaged by
arrowheads. Bar graphs show the percentage of intracellular granules that
(CK1δ+), or double-stained with MARK3 and CK1δ (MARK3+CK1δ+) or MARK
granules. MARK4+ granules were significantly larger than MARK4+CK1δ+ an
not significantly different. Data depict means ± SEM. *p < 0.05, by 1-way AN
bars: 10 μm.sities of the bands above background levels were mea-
sured using a BioRad GS-800 Calibrated Densitometer
using Quantity One 4.6.4 software. The optical densities
for MARK3 and MARK4 were normalized to β-actin.
Results
Widespread neuronal expression of MARK1-4 mRNA in
hippocampus
To study mRNA expression of MARK1-4 in the hippo-
campus we performed in situ hybridization on sections
from NDE and AD cases with specific probes towards each
individual MARK isoform (Figure 1A-D). Hybridization
was particularly strong in neuronal layers and was intense
in the dentate gyrus and cornu ammonis (CA), being
weaker in the subiculum and entorhinal cortex. Emulsion-
dipped and counter-stained sections confirmed that ex-
pression was localized to neurons (Figure 1E). Strikingly,
the mRNA expression pattern was practically identical be-
tween isoforms and there was similar expression in both
NDE and AD cases.
MARK3 and MARK4 are elevated in AD
To assess the protein expression of individual MARK
isoforms we used a set of isoform- specific antibodies
that was verified in a previous study [13] to stain hippo-
campus sections of several NDE and AD cases (Table 1).
The general localization of MARK1-3 in the hippocam-
pus is depicted in Figure 2. MARK1 and MARK2
immunoreactivity was recorded in the cytoplasm of CA
neurons and in the neuropil (Figure 3A-D), the stainingker CK1δ. Double-immunofluorescence with (A) MARK3 (FITC) or
aining neurons in the CA1-CA2 area. Images are compressions of a
confocal microscopy showing colocalization in the GVD indicated by
were single stained with MARK3 (MARK3+), MARK4 (MARK4+) or CK1δ
4 and CK1δ (MARK4+ CK1δ+), as well as the average size of these
d CK1δ+ granules. MARK3+, MARK3+CK1δ+ or CK1δ+ granules size was
OVA with Bonferroni’s Multiple Comparison test, (n = 4–6 cases). Scale
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immunoreactivity was weak in the cytoplasm but in
some cases stained granular deposits in certain neurons
(Figure 3E-F). These deposits were observed in all AD
cases, particularly in the CA1-CA2 region and more
rarely in the CA3-CA4 region. Only a few stained de-
posits were observed in NDE cases and then only in
CA1-CA2. The MARK4 antibody produced no detect-
able diffuse immunoreactivity in the cytoplasm of either
NDE or AD cases, but stained granular deposits in neu-
rons that were particularly numerous in CA1-CA2 and
to a lesser extent in CA3-CA4. These MARK4-positive
granules were particularly abundant in AD cases and
were practically absent in NDE cases (Figure 3G-H).
To quantify expression levels we counted the number
of neurons that contained MARK3 or MARK4 immuno-
reactive granules in the CA1-CA2 and CA3-CA4 areas.
Since the granules resembled granulovacuolar degener-
ation bodies (GVDs) [30,32], we stained sections in par-
allel using the GVD-marker CK1δ [28] and counted
the number of immunoreactive neurons (Figure 3I). We
found a remarkable enhancement in all three markers in
AD cases compared to NDE cases in both CA1-CA2
and CA3-CA4. The number of MARK4 and CK1δ neu-
rons were very similar in all areas whereas MARK3 im-
munoreactivity was only found in 20% of the number of
MARK4+ or CK1δ+ neurons. Interestingly, the number
of MARK3+, MARK4+ or CK1δ+ neurons appeared to beFigure 5 Western blot of MARK3 and MARK4 in hippocampal homog
immunoreactivities in hippocampal homogenates from 4 NDE and 3 AD ca
served as positive controls, whereas non-transfected HEK cells served as ne
content in the homogenates. (B) Quantification of full-length (84 respective
β-actin band density. No full-length MARK4 band could be identified or me
Student’s unpaired two-tailed t-test.Braak-stage dependent. The number of immunoreactive
neurons increased with all markers from Braak stage 0-V
after which a small decrease between Braak stage V and VI
was observed (Figure 3J). GVDs were not stained with
either MARK1 or MARK2 antibodies (Figure 3B, D).
To more specifically determine how much of the
MARK3 and MARK4 staining was found in GVDs
we performed double-immunofluorescence staining with
MARK3 or MARK4 and CK1δ, respectively. We then
scanned several GVD-containing neurons/case where
both markers were present with confocal microscopy
and quantified the number and size of intracellular parti-
cles that were single stained (MARK3+, MARK4+ or
CK1δ+) or double-stained (MARK3+CK1δ+ or MARK4+
CK1δ+). Although intracellular MARK3 granules al-
most invariably coincided with the presence of CK1δ
granules, only 10% of the granules were MARK3+CK1δ+.
The remaining granules consisted of 47% MARK3+ and
43% CK1δ+ (Figure 4A). We found that MARK4+ gran-
ules accounted for about 42% of the total number of
intracellular granules, 26% were CK1δ+ and 32% were
MARK4+CK1δ+ (Figure 4B).
To further quantify the expression of MARK3 and
MARK4 we performed Western blotting of hippocampal
homogenates from NDE and AD cases. Preparations of
HEK cells transfected with MARK3 or MARK4 were
used as positive control, and here the MARK3 and
MARK4 antibodies recognized bands that correspondedenates. (A) Western blots showing MARK3 (top) and MARK4 (bottom)
ses. HEK cells transfected with either MARK3 or MARK4, respectively,
gative control. β-actin served as a normalizing control for protein
82 kDa) and shorter (40–65 kDA) band densities normalized against
asured. Data depicts means ± SEM. *p < 0.05, ns non-significant by
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ively. In hippocampal homogenates full-length MARK3
could be detected and measured (Figure 5A), but there
was no significant difference between NDE and AD
cases when the band density was normalized against
β-actin (Figure 5B). Remarkably, no full-length MARK4
was detectable in the brain samples (Figure 5A). This
was not due to a problem with the antibody, since a full-
length MARK4 band was clearly detectable in MARK4-
transfected cells. However, both antibodies recognized a
number of bands in the 40–65 kDa region, and when
the densities were normalized against β-actin a signifi-
cant increase in AD over NDE cases was observed on
both MARK3 and MARK4 blots (Figure 5B).Figure 6 Expression of MARK4 and p-tau Ser262 in hippocampi with in
adjacent sections from the CA1-CA2 field of three cases (#6, #31 and #29) w
and p-tau Ser262 antibodies. Arrowheads indicate neurons that stain positiv
adjacent section are also intensely stained with the p-tau Ser262 antibody. SMARK4 co-expresses with p-tau Ser262 in a Braak-stage
dependent manner
Since MARK4 was the major isoform present in GVDs
and most strongly elevated in AD cases, we chose to
continue to study the MARK4 isoform in relation to
neurofibrillary changes. We stained adjacent sections of
eight cases with the MARK4 antibody and an antibody
specific for the phosphorylated Ser262 site of tau. We ob-
served an increase in the number of MARK4 positive
neurons with increasing Braak stage. Interestingly, this
seemed to correlate very well with tau phosphorylation
at the Ser262 epitope, which is a MARK substrate.
Practically every neuron that contained MARK4 immu-
noreactivity also contained phosphorylated Ser262 tau.creasing neurofibrillary pathology. Photomicrographs of exactly
ith increasing degree of neurofibrillary pathology, stained with MARK4
e for MARK4, which increase with Braak stage. Those neurons in the
cale bar: 50 μm.
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stages, whereby the few neurons containing MARK4 also
had phosphorylated Ser262 tau (Figure 6). Tau itself was
not enriched in the GVDs (Figure 7).
MARK4 in GVDs is in a phosphorylated and activated
form
Since MARKs can be activated by phosphorylation in
the activation loop [33] we wanted to determine if
MARK4 was phosphorylated in GVDs. We therefore
used an antibody that recognizes the phosphorylation of
threonine in the activation epitope common for all
MARK isoforms (Thr214 on MARK4). We determined
that the phospho-specific MARK antibody produced a
staining pattern very similar to that of the MARK4
antibody, which was confirmed by double-immunofluor-
escence. This indicates that MARK4 is phosphorylated
and present in an activated form in GVD neurons. When
sections were triple-labeled with MARK4, pMARK, and
p-tau Ser262 antibodies, the phosphorylated MARK4 pro-
tein often coincided with p-tau Ser262 staining (Figure 8).
To investigate whether other non-MARK p-tau epitopes
were present in GVDs we stained sections with the p-tau
Ser262 antibody as well as three well-characterized anti-
bodies towards p-tau Ser202/Ser205 (AT8), Ser212/Thr214
(AT100) and Ser422. Interestingly, while all four antibodies
stained fibrillar tau and neuropil threads, only the p-tau
Ser262 antibody stained granular deposits in the soma
(Figure 9).
Discussion
The mRNA levels of all MARKs were similar between
AD and NDE and did not correlate with pathological
changes. This indicates that transcription of MARK genes
is unaffected in AD. Whereas the uniform neuronal ex-
pression of MARK1, 2, and 3 mRNAs was reflected by a
cytoplasmic expression of the corresponding protein inFigure 7 Expression of total tau in the hippocampus. High magnificati
with an antibody towards non-phosphorylated tau (tau-13). (A) Tau-13 imm
the soma, except in NFT-containing neurons (arrowhead). However, granul
antibody. The AD case (B) contained overall more intense staining in the s
ity was not enriched in GVDs. Scale bar: 25 μm.neurons, there was no noticeable cytoplasmic MARK4
protein expression and hence MARK4 was entirely absent
in healthy neurons. This absence was not due to lack of
MARK4 affinity, as the antibody detected MARK4 in co-
transfected HEK cells. In a previous study we observed
low cytoplasmic MARK4 expression in NDE cases using
the in situ proximity ligation assay [13]. This is likely due
to the higher sensitivity achieved using the proximity
ligation method, but could also reflect the recognition of
neurons in which pathological MARK phosphorylation
has begun. It is worth noting that both fresh-frozen and
formalin-fixed paraffin embedded tissues were used, with
identical staining pattern. The very low MARK4 protein
expression in NDE cases was confirmed by Western blot-
ting, which did not detect full-length MARK4. This appar-
ent absence of MARK4 protein may be due to that the
expression level is below the limit of detection using the
present methodologies, but could also perhaps be due to
some unknown post-translational modification at the epi-
tope site that disturbs both immunohistochemical and
biochemical detection in the post-mortem tissues.
In contrast to the very low expression in NDE, we ob-
served a prominent expression of MARK4 protein in
AD tissues. It is interesting that MARK4 is specifically
elevated, particularly since a locus near the MARK4
gene has recently been described to have genome-wide
significance for AD [34]. MARK3 and MARK4 granules
coincided with the presence GVDs (as determined by
CK1δ+ granules), which are defined as electron-dense
granules within double membrane-bound cytoplasmic
vacuoles, and that are believed to be part of the autopha-
gic system [22,32]. Interestingly, it was demonstrated in
a recent report that the level of GVDs increases steadily
with AD progression, correlating with Braak stage,
CERAD score, amyloid beta phase and cognitive state,
but does not correlate in other non-AD tauopathies
[30]. Another recent study corroborates the view thaton micrographs of one NDE (A; #6) and one AD (B; #34) case stained
unoreactivity in the NDE case was strong in the neuropil and weak in
ar immunoreactivity or GVD staining was not observed with the tau-13
omatodendritic compartment (arrowheads), but tau-13 immunoreactiv-
Figure 8 Colocalization of MARK4, phospho-MARK, and p-tau Ser262 in GVDs. Triple-immunofluorescence images from the CA1-field of an
AD case (#32) with antibodies against pMARK (FITC), MARK4 (Cy3) and p-tau Ser262 (Cy5). (A) Arrowheads indicate neurons that stain positively
for all three antibodies. (B) A typical pre-tangle neuron with perinuclear phospho-tau staining is magnified, where arrowheads indicate individual
GVDs where all three markers colocalize. (C) A 3-D reconstruction of a Z-stack focused on the GVD in the bottom part of the neuron. Scale bar:
100 μm.
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ated [35].
The distribution of MARK3 and MARK4 granules in
CA-neurons correlated well with CK1δ granules and all
three markers increased in a Braak-stage dependent
manner, except for a small attenuation in CA1-CA2 at
Braak stage VI. This attenuation is likely due to the se-
vere neuron loss observed in this area at this Braak
stage, since the data was expressed in neurons/mm2 and
not percent of total neurons. Interestingly, only 32% of
intracellular granules were MARK4+CK1δ+ and as few
as 10% were MARK3+CK1δ+. Furthermore, MARK4+
granules were significantly larger in size than CK1δ+ or
MARK4+CK1δ+ granules. Taken together, this suggests
that although MARK3 and MARK4, along with CK1δare sequestered in a GVD-dependent manner, CA-neurons
utilize different intracellular pathways to sequester these
kinases. The relatively large size of the MARK4+ granules
as compared to the CK1δ+ granules could possibly indicate
that MARK4+ granules represent a more mature form of
GVDs.
The exact role of these events in neuropathological
progression in AD remains to be elucidated. It is well
established that there is a spatiotemporal progression of
neurofibrillary pathology in the brain, with certain areas
being affected before others. The entorhinal cortex be-
comes affected at an early stage with subsequent appear-
ance of NFTs in the CA1-field [36]. Conversion of
individual neurons into NFTs is also suggested to occur
in a hierarchical sequence of phosphorylation events,
Figure 9 Examination of tau phosphorylation sites in GVDs. Double immunofluorescence of two adjacent sections from the CA1 of an AD
case (#18) with four p-tau specific antibodies: Ser212/Thr214 (AT100, FITC), Ser262 (Cy3), Ser202/Thr205 (AT8, FITC), Ser422 (Cy3). Neurofibrillary tangles
(arrows) and neuropil threads (arrowheads) are stained with all four antibodies. The magnified neuron is stained with all four antibodies, and only
the Ser262 site can be observed in granular deposits in the cytoplasm (arrowheads in inset), corresponding to GVDs. Intraneuronal accumulation
of fibrillar tau is stained with all antibodies. Scale bar: 25 μm.
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mation of a NFT when the neuron is in a pretangle stage
[9,37]. Herein we demonstrate that the first appearance
of Ser262 phosphorylation in the CA-field is paralleled by
an activation of the GVD system and particularly by
strong MARK4 expression. In CA1 in the early Braak
stages, tau Ser262 is initially only evident in a very limited
number of neurons, and although present in the cyto-
plasm is highly concentrated in the GVDs. According to
the GVD-staging proposed by Thal et al. [30], GVD
pathology first appears in CA1-neurons and only in later
stages in the entorhinal cortex. The fact that GVD for-
mation is first apparent in CA1-neurons could be due
to a higher sensitivity of these neurons to tau phosphor-
ylation, or alternatively a higher ability to engage au-
tophagic GVD processes as a defence mechanism. In
concordance with this latter hypothesis, induction of au-
tophagy has recently been shown to be able to reduce
levels of phosphorylated tau in neurons [38]. It can be
hypothesized that this early phosphorylation of tau
Ser262 is driven by increased activities of cytoplasmic
MARK2, MARK3 and very low levels of MARK4.
This hypothesis is partly supported by the increasedassociation of MARK2 and MARK4 to tau in the soma-
todendritic compartment, shown in a previous study
[13]. Phosphorylation at tau Ser262 will lead to subse-
quent phosphorylation at other tau epitopes which will
cause detachment from microtubules and make tau
available for aggregation into NFTs [10].
MARK4 in the GVDs was highly phosphorylated, indi-
cative of the presence in a high activity form. MARKs
contain numerous kinase-regulated sites [39,40] and, for
example, phosphorylation at the Thr214 site (of MARK4
sequence) can increase MARK activity >50 times [33].
However, the exact mechanism involved in activation of
MARK4 in AD, and the possible link to amyloid beta
oligomers [41] remains to be established.
It is possible that MARK3 and 4 are phosphorylated
and activated within the GVDs, but alternatively the
activation may already have occurred in the neuronal
cytoplasm. If so, there appears to be a very effective se-
questering by the GVDs since we could not detect
any phosphorylated and activated MARK4 or MARK3
in the cytosolic compartment. MARK4 in GVDs appears
to undergo proteolysis since only shorter bands were
observed in the immunoblots and these bands had
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http://www.actaneurocomms.org/content/2/1/22increased in intensity in AD. That the 40–65 kDa bands
represent proteolytic products within the GVDs is also
consistent with the lack of similar bands in HEK cell ly-
sates. However, it cannot be excluded that they to some
extent represent non-specific cross-reactive bands.
The detection of bands representing truncated protein
evident in the NDE cases probably reflects the rare pres-
ence of GVDs at these early Braak stages. A similar pat-
tern was observed for MARK3, whereby an increase of
truncated forms of MARK3 in immunoblots corre-
sponds to an increased expression in AD by appearing
in a minor fraction of GVDs. In contrast, full- length
MARK3 was not elevated in AD and therefore presum-
ably reflects the cytoplasmic component that is similar
between NDE and AD cases.
It is possible that MARK4 and to some extent MARK3
become sequestered and that they phosphorylate tau
already present in the GVDs at Ser262, due to the closer
proximity between substrate and enzyme [13], as well as
due to the activated state of MARK3 and MARK4. Alter-
natively, Ser262 may already be phosphorylated in the tau
molecules sequestered into the GVDs, and sequestering
of tau phosphorylated Ser262 into GVDs would confer
prevention of subsequent phosphorylation at other epi-
topes and tangle formation. In fact, subsequent phos-
phorylation at Ser202/Thr205 (AT8), Thr212/Ser214 (AT100),
and Ser422 are absent in the GVDs, in spite of the presence
of many tau phosphorylating enzymes such as CK1δ
[26,28], GSK3β in its active form [27] and CDK5 [42]. It
should be noted that our results on this matter conflict
slightly with those of Leroy et al. [27] who found not only
p-tau Ser262 but also AT100 immunoreactivity (although
to a lesser extent) in GVDs. An early study also identified
GVD immunoreactivity using the Tau-1 antibody in de-
phosphorylated brain tissues, suggesting the presence of
the p-Ser199 epitope [1,43]. In further support of this hy-
pothesis, Ikegami et al. could not find PHF-structures
upon ultrastructural examination of GVDs, indicating the
presence of pre-PHF tau [44]. It should be noted though
that total tau does not accumulate into GVD as a result of
such possible sequestering. Moreover, it is interesting to
note that CaMKII, which accounts for a large portion of
normal brain p-Ser262 activity [45] has not been found in
GVDs in three immunohistochemical studies of AD
hippocampus [46-48].
The cytoplasmic phosphorylation of tau steadily in-
creases with time, likely driven by cytosolic MARK2.
This notion is supported by an increased MARK2-tau
interaction in this compartment [13,21], as well as a
complete lack of immunoreactivity in GVDs. Hence a
continuous cytoplasmic presence of active MARK2 may
allow a slow but steady continuous cytosolic phosphoryl-
ation at other p-tau sites, a process that GVD-mediated
autophagy cannot prevent. The presumed protectiveeffect of GVDs ultimately fails at later Braak stages,
either due to a diminished capacity of GVDs to seques-
ter p-tau Ser262 or due to breakdown of GVDs with sub-
sequent release of their components into the cytosol.
Together these events lead to the cytoplasmic neuronal
compartment filling up with tau phosphorylated at mul-
tiple sites available for further aggregation into NFTs,
which in turn may result in neuronal degeneration and
associated cognitive decline.
There is presently no evidence for an involvement of
MARK1 in any of these pathological events. A previous
investigation of MARK expression in human brain tis-
sues reported increased levels of MARK1 in AD in tau
tangle-containing neurons [20], in contrast with current
and previous [13] findings, and this discrepancy could
be due to less specific antibodies used in that study. An-
other report described an association between active
MARK and neurofibrillary tangles but did not further
describe the antibody characteristics [49].
Conclusion
In the present study we demonstrate that phosphory-
lated MARK4 and to some extent MARK3 are highly
localized to GVD expressing neurons and that this ex-
pression is strongly correlated with phosphorylation of
tau at Ser262. This may represent a cellular defense
mechanism to remove activated MARK and p-tau Ser262
from the cytosol, thereby reducing the phosphorylating
effect on tau Ser262 that appears to be a critical step for
subsequent neurodegeneration in AD.
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